Drug intelligence / Profile preview

FoliaPRÉ

Development stage: Unknown
Lead developer: Laboratório Gross
Modality: Small Molecules
Administration: Oral

Overview

FoliaPRÉ is a multi-ingredient dietary supplement developed by Laboratório Gross S.A., specifically formulated for women in the preconception phase and the first trimester of pregnancy. The product contains a combination of L-methylfolate calcium (the bioactive form of folate), cholecalciferol (Vitamin D3), pyridoxine hydrochloride (Vitamin B6), cyanocobalamin (Vitamin B12), and potassium iodide (iodine). It is designed to optimize maternal nutritional status, support healthy fetal neurological development, and reduce the risk of neural tube defects. As a nutraceutical product marketed in Brazil, it provides essential micronutrients required for early embryonic growth and cellular division.

Brand names: FoliaPRÉ
Other names: Folia PRE

Targets

FOLR1 (FRα)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on FoliaPRÉ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FoliaPRÉ.

Explore the full profile